Evidence map›Paper›PMID 29725035›Full record

ArticleScientific reports2018

White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients.

Oriana Salamo, Shiva Roghaee, Michael D Schweitzer, Alejandro Mantero, Shirin Shafazand, Michael Campos, Mehdi Mirsaeidi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Sarcoidosis-associated pulmonary fibrosis: joining the dots.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  3. The therapy of idiopathic pulmonary fibrosis: what is next?European respiratory review : an official journal of the European Respiratory Society · 2019
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Oriana SalamoSection of Pulmonary, Miami VA Healthcare System, Miami, FL, USA.
Shiva RoghaeeSection of Pulmonary, Miami VA Healthcare System, Miami, FL, USA.
Michael D SchweitzerSection of Pulmonary, Miami VA Healthcare System, Miami, FL, USA.
Alejandro ManteroDepartment of Public Health, Division of Biostatistics, University of Miami, Miami, FL, USA.
Shirin ShafazandDivision of Pulmonary and Critical Care, University of Miami, Miami, FL, USA.
Michael CamposSection of Pulmonary, Miami VA Healthcare System, Miami, FL, USA.
Mehdi MirsaeidiSection of Pulmonary, Miami VA Healthcare System, Miami, FL, USA. msm249@med.miami.edu.ORCID 0000-0001-5298-8442
University of Miami · USMiami VA Healthcare System · US

Funding

Miami Clinical and Translational Science InstituteUL1TR000460 · NCATS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SACCO, RALPH L. · 2012 to 2016
$16.9M
NCATS NIH HHS UL1 TR000460
6 · The paper itself

Abstract

Sarcoidosis commonly affects the lung. Lung transplantation (LT) is required when there is a severe and refractory involvement. We compared post-transplant survival rates of sarcoidosis patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). We also explored whether the race and age of the donor, and double lung transplant have any effect on the survival in the post transplant setting. We analyzed 9,727 adult patients with sarcoidosis, COPD, and IPF who underwent LT worldwide between 2005-2015 based on United Network for Organ Sharing (UNOS) database. Survival rates were compared with Kaplan-Meier, and risk factors were investigated by Cox-regression analysis. 469 (5%) were transplanted because of sarcoidosis, 3,688 (38%) for COPD and 5,570 (57%) for IPF. Unadjusted survival analysis showed a better post-transplant survival rate for patients with sarcoidosis (p < 0.001, Log-rank test). In Cox-regression analysis, double lung transplant and white race of the lung donor showed to have a significant survival advantage. Since double lung transplant, those who are younger and have lower Lung Allocation Score (LAS) at the time of transplant have a survival advantage, we suggest double lung transplant as the procedure of choice, especially in younger sarcoidosis subjects and with lower LAS scores.

Indexed as

Donor SelectionLung TransplantationAdultAgedAge FactorsFemaleGraft SurvivalHumansIdiopathic Pulmonary FibrosisMaleMiddle AgedProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveSarcoidosis, PulmonarySurvival AnalysisSurvival Rate

Identifiers

PMID29725035
PMCPMC5934355
OpenAlexW2800201973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.